KR20170033427A - 증식성 질병 치료용 [1,2,4]트리아졸로[4,3-b]피리다진 - Google Patents

증식성 질병 치료용 [1,2,4]트리아졸로[4,3-b]피리다진 Download PDF

Info

Publication number
KR20170033427A
KR20170033427A KR1020177005146A KR20177005146A KR20170033427A KR 20170033427 A KR20170033427 A KR 20170033427A KR 1020177005146 A KR1020177005146 A KR 1020177005146A KR 20177005146 A KR20177005146 A KR 20177005146A KR 20170033427 A KR20170033427 A KR 20170033427A
Authority
KR
South Korea
Prior art keywords
compound
formula
pharmaceutically acceptable
acceptable salt
methoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020177005146A
Other languages
English (en)
Korean (ko)
Inventor
로버트 허그 브래드버리
알프레드 아서 라보우
마이클 제임스 워링
제임스 프란시스 맥카베
스티븐 크리스토퍼 글로솝
아르쉐드 마무드
조에 안 코터
Original Assignee
아스트라제네카 아베
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아스트라제네카 아베 filed Critical 아스트라제네카 아베
Publication of KR20170033427A publication Critical patent/KR20170033427A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/105—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic
    • C07C65/11—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic with carboxyl groups on a condensed ring system containing two rings
    • E—FIXED CONSTRUCTIONS
    • E21—EARTH OR ROCK DRILLING; MINING
    • E21B—EARTH OR ROCK DRILLING; OBTAINING OIL, GAS, WATER, SOLUBLE OR MELTABLE MATERIALS OR A SLURRY OF MINERALS FROM WELLS
    • E21B7/00—Special methods or apparatus for drilling
    • E21B7/04—Directional drilling
    • E21B7/06—Deflecting the direction of boreholes
    • E—FIXED CONSTRUCTIONS
    • E21—EARTH OR ROCK DRILLING; MINING
    • E21B—EARTH OR ROCK DRILLING; OBTAINING OIL, GAS, WATER, SOLUBLE OR MELTABLE MATERIALS OR A SLURRY OF MINERALS FROM WELLS
    • E21B7/00—Special methods or apparatus for drilling
    • E21B7/04—Directional drilling
    • E21B7/06—Deflecting the direction of boreholes
    • E21B7/062—Deflecting the direction of boreholes the tool shaft rotating inside a non-rotating guide travelling with the shaft
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Geology (AREA)
  • Mining & Mineral Resources (AREA)
  • Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Environmental & Geological Engineering (AREA)
  • Fluid Mechanics (AREA)
  • General Life Sciences & Earth Sciences (AREA)
  • Geochemistry & Mineralogy (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020177005146A 2014-07-28 2015-07-24 증식성 질병 치료용 [1,2,4]트리아졸로[4,3-b]피리다진 Ceased KR20170033427A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462029676P 2014-07-28 2014-07-28
US62/029,676 2014-07-28
PCT/GB2015/052143 WO2016016618A1 (en) 2014-07-28 2015-07-24 [1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases

Publications (1)

Publication Number Publication Date
KR20170033427A true KR20170033427A (ko) 2017-03-24

Family

ID=53761420

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177005146A Ceased KR20170033427A (ko) 2014-07-28 2015-07-24 증식성 질병 치료용 [1,2,4]트리아졸로[4,3-b]피리다진

Country Status (37)

Country Link
US (5) US9944650B2 (enExample)
EP (1) EP3174881B1 (enExample)
JP (1) JP6592503B2 (enExample)
KR (1) KR20170033427A (enExample)
CN (1) CN106536524B (enExample)
AP (1) AP2017009700A0 (enExample)
AU (1) AU2015295120B2 (enExample)
BR (1) BR112017001160A2 (enExample)
CA (2) CA2956421C (enExample)
CL (1) CL2017000223A1 (enExample)
CO (1) CO2017001918A2 (enExample)
CY (1) CY1120602T1 (enExample)
DK (1) DK3174881T3 (enExample)
DO (1) DOP2017000018A (enExample)
EA (1) EA032654B9 (enExample)
ES (1) ES2670444T3 (enExample)
GT (1) GT201700016A (enExample)
HR (1) HRP20180788T1 (enExample)
HU (1) HUE037571T2 (enExample)
IL (1) IL250104B (enExample)
LT (1) LT3174881T (enExample)
MX (1) MX374539B (enExample)
MY (1) MY187251A (enExample)
NI (1) NI201700006A (enExample)
NO (2) NO2719005T3 (enExample)
PE (1) PE20170527A1 (enExample)
PH (1) PH12017500159B1 (enExample)
PL (1) PL3174881T3 (enExample)
PT (1) PT3174881T (enExample)
RS (1) RS57242B1 (enExample)
SG (1) SG11201700419SA (enExample)
SI (1) SI3174881T1 (enExample)
SM (1) SMT201800260T1 (enExample)
SV (1) SV2017005368A (enExample)
TN (1) TN2017000018A1 (enExample)
WO (1) WO2016016618A1 (enExample)
ZA (1) ZA201701207B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2719005T3 (enExample) * 2014-07-28 2018-01-20
CN110317216A (zh) * 2018-03-28 2019-10-11 首都医科大学 一种三唑并哒嗪类衍生物在医药领域的应用
TWI816880B (zh) * 2018-09-13 2023-10-01 大陸商恒翼生物醫藥(上海)股份有限公司 治療前列腺癌之組合療法
MX2022004555A (es) 2019-10-14 2022-07-21 Astrazeneca Ab Terapia de combinacion para tratar una neoplasia maligna hematologica.
JP2023509191A (ja) 2020-01-09 2023-03-07 アストラゼネカ・アクチエボラーグ 癌を治療するための組み合わせ療法
CN113143930B (zh) * 2021-04-08 2023-05-30 深圳湾实验室 化合物在制备SARS-Cov-2 E蛋白抑制剂中的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7795273B2 (en) 2005-12-08 2010-09-14 Novartis Ag Pyrazolo[1,5-a]pyridine-3-carboxylic acids as EphB and VEGFR2 kinase inhibitors
GB0525065D0 (en) * 2005-12-08 2006-01-18 Novartis Ag Organic compounds
CN101952286A (zh) 2007-12-21 2011-01-19 阿斯利康(瑞典)有限公司 用于治疗和雄激素受体有关的病症的双环衍生物
WO2010092371A1 (en) * 2009-02-10 2010-08-19 Astrazeneca Ab Triazolo [4,3-b] pyridazine derivatives and their uses for prostate cancer
EP2430024A1 (en) * 2009-05-11 2012-03-21 AstraZeneca AB [1,2,4]triazolo [4,3-b]pyridazines as ligands of the androgen receptor
CA2779355C (en) 2009-11-05 2018-01-16 Glaxosmithkline Llc Benzodiazepine bromodomain inhibitor
WO2012174487A2 (en) * 2011-06-17 2012-12-20 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
US9422290B2 (en) 2012-11-13 2016-08-23 Boehringer Ingelheim International Gmbh Triazolopyridazine
NO2719005T3 (enExample) * 2014-07-28 2018-01-20

Also Published As

Publication number Publication date
MY187251A (en) 2021-09-15
AU2015295120A8 (en) 2017-02-09
EA032654B1 (ru) 2019-06-28
SI3174881T1 (en) 2018-06-29
EP3174881B1 (en) 2018-03-28
AP2017009700A0 (en) 2017-01-31
PH12017500159A1 (en) 2017-07-10
IL250104A0 (en) 2017-03-30
PH12017500159B1 (en) 2020-12-09
US9944650B2 (en) 2018-04-17
NI201700006A (es) 2017-08-25
HUE037571T2 (hu) 2018-09-28
NO3174881T3 (enExample) 2018-08-25
PT3174881T (pt) 2018-05-25
ES2670444T3 (es) 2018-05-30
US11407755B2 (en) 2022-08-09
JP6592503B2 (ja) 2019-10-16
JP2017522338A (ja) 2017-08-10
SMT201800260T1 (it) 2018-07-17
US20200055861A1 (en) 2020-02-20
SG11201700419SA (en) 2017-02-27
US10407432B2 (en) 2019-09-10
EA201790179A1 (ru) 2017-07-31
AU2015295120A1 (en) 2017-02-02
SV2017005368A (es) 2017-05-12
CY1120602T1 (el) 2019-12-11
CN106536524A (zh) 2017-03-22
DOP2017000018A (es) 2017-03-15
ZA201701207B (en) 2018-12-19
LT3174881T (lt) 2018-06-11
CO2017001918A2 (es) 2017-05-10
BR112017001160A2 (pt) 2017-11-14
MX374539B (es) 2025-03-06
DK3174881T3 (en) 2018-06-06
US20180230158A1 (en) 2018-08-16
WO2016016618A1 (en) 2016-02-04
GT201700016A (es) 2018-12-19
MX2017001218A (es) 2017-05-01
PE20170527A1 (es) 2017-05-24
US20170210747A1 (en) 2017-07-27
EP3174881A1 (en) 2017-06-07
IL250104B (en) 2018-10-31
EA032654B9 (ru) 2019-07-31
CL2017000223A1 (es) 2017-08-25
CA2956421C (en) 2023-03-14
CA3185741A1 (en) 2016-02-04
TN2017000018A1 (en) 2018-07-04
US10766905B2 (en) 2020-09-08
AU2015295120B2 (en) 2018-02-01
PL3174881T3 (pl) 2018-08-31
US20210107905A1 (en) 2021-04-15
RS57242B1 (sr) 2018-07-31
US20230035133A1 (en) 2023-02-02
HRP20180788T1 (hr) 2018-06-29
NO2719005T3 (enExample) 2018-01-20
CA2956421A1 (en) 2016-02-04
CN106536524B (zh) 2019-11-15

Similar Documents

Publication Publication Date Title
US11407755B2 (en) [1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases
EP3596073B1 (en) Tricyclic compounds for use in treatment of proliferative disorders.
AU2018235139A1 (en) Compounds useful in the treatment or prevention of a PRMT5-mediated disorder
US20240408064A1 (en) Ras inhibitors, compositions and methods of use thereof
EP3189048A1 (en) Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived prmt5-inhibitors
JP2019526605A (ja) 置換2−h−ピラゾール誘導体の結晶形、塩型及びその製造方法
TW201728577A (zh) 作為nik抑制劑的新穎的經取代氰基吲哚啉衍生物
CA2749926A1 (en) Triazolo [4,3-b] pyridazine derivatives and their uses for prostate cancer
AU2022340743A1 (en) Mixed lineage kinase inhibitors and methods of use
US20100292222A1 (en) Chemical compounds 751
HK1235059A1 (en) [1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases
HK1235059B (en) [1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases
BR112019025836A2 (pt) composto de aminopirimidina, método de preparação do mesmo e uso do mesmo
BR112019025836B1 (pt) Composto de aminopirimidina, seu método de preparação, composição farmacêutica e seu uso

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170223

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200603

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220720

Patent event code: PE09021S01D

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20230116

Patent event code: PE09021S02D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20230413

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230116

Comment text: Final Notice of Reason for Refusal

Patent event code: PE06011S02I

Patent event date: 20220720

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I